T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus

Francesco Dotta, Sabrina Dionisi, Vissia Viglietta, Claudio Tiberti, Maria Cristina Matteoli, Marco Cervoni, Carla Bizzarri, Giovanni Marietti, Manuela Testi, Giuseppe Multari, Lucio Lucentini, Umberto Di Mario

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The target molecules of the T-cell response in type 1 diabetes, despite their pathogenic importance, remain largely uncharacterized, especially in humans. Interestingly, molecules such as insulin and glutamic acid decarboxylase (GAD) have been shown to be a target not only of autoantibodies, but also of autoreactive T-lymphocytes both in man and in the non-obese diabetic (NOD) mouse. In the present study we aimed to determine the existence of a specific T-cell response towards the insulinoma-associated protein 2 (IA-2) islet tyrosine phosphatase, a recently identified autoantigen which is the target of autoantibodies strongly associated with diabetes development. Human recombinant IA-2 produced in Escherichia coli, was tested for its reactivity with peripheral blood lymphocytes obtained from 16 newly diagnosed type i diabetic patients and from 25 normal controls, 15 of whom were HLA-DR-matched. A T-cell proliferation assay was performed in triplicate employing freshly isolated cells in the absence or in the presence of the antigen to be tested (at two different concentrations: 2 μg/ml and 10 μg/ml). A specific T-cell proliferation (defined as a stimulation index (S.I.) ≥3) was observed against IA-2 used at a concentration of 10 μg/ml (but not of 2 μg/ml) in 8/16 diabetic patients, in 1/15 HLA-DR-matched control subjects (P <0.01 by Fisher exact test) and in 0/10 of the remaining normal individuals. A statistically significant difference (P <0.003 by Mann-Whitney U test) was also observed in S.I. values between patients (3.1 ± 1.4) and HLA-DR-matched controls (1.7 ± 0.54) employing IA-2 at a concentration of 10 μg/ml. However, when IA-2 was used at a concentration of 2 μg/ml, the difference in S.I. between patients (1.65 ± 0.8) and controls (1.0 ± 0.3) did not reach statistical significance. In conclusion, these data show the presence of a specific, dose-dependent T-lymphocyte response against the IA-2 islet tyrosine phosphatase at the onset of type 1 diabetes. Consequently, this molecule appears to be a target not only at the B- lymphocyte but also at the T-lymphocyte level, reinforcing the potential pathogenic role of this autoantigen in the islet destructive process.

Original languageEnglish
Pages (from-to)272-278
Number of pages7
JournalEuropean Journal of Endocrinology
Volume141
Issue number3
DOIs
Publication statusPublished - Sep 1999

Fingerprint

Class 8 Receptor-Like Protein Tyrosine Phosphatases
Autoimmunity
Type 1 Diabetes Mellitus
Phosphoric Monoester Hydrolases
T-Lymphocytes
HLA-DR Antigens
Autoantigens
Autoantibodies
Cell Proliferation
Inbred NOD Mouse
Glutamate Decarboxylase
Nonparametric Statistics
2-tyrosine
B-Lymphocytes
Lymphocytes
Insulin
Escherichia coli
Antigens

ASJC Scopus subject areas

  • Endocrinology

Cite this

Dotta, F., Dionisi, S., Viglietta, V., Tiberti, C., Matteoli, M. C., Cervoni, M., ... Di Mario, U. (1999). T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. European Journal of Endocrinology, 141(3), 272-278. https://doi.org/10.1530/eje.0.1410272

T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. / Dotta, Francesco; Dionisi, Sabrina; Viglietta, Vissia; Tiberti, Claudio; Matteoli, Maria Cristina; Cervoni, Marco; Bizzarri, Carla; Marietti, Giovanni; Testi, Manuela; Multari, Giuseppe; Lucentini, Lucio; Di Mario, Umberto.

In: European Journal of Endocrinology, Vol. 141, No. 3, 09.1999, p. 272-278.

Research output: Contribution to journalArticle

Dotta, F, Dionisi, S, Viglietta, V, Tiberti, C, Matteoli, MC, Cervoni, M, Bizzarri, C, Marietti, G, Testi, M, Multari, G, Lucentini, L & Di Mario, U 1999, 'T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus', European Journal of Endocrinology, vol. 141, no. 3, pp. 272-278. https://doi.org/10.1530/eje.0.1410272
Dotta, Francesco ; Dionisi, Sabrina ; Viglietta, Vissia ; Tiberti, Claudio ; Matteoli, Maria Cristina ; Cervoni, Marco ; Bizzarri, Carla ; Marietti, Giovanni ; Testi, Manuela ; Multari, Giuseppe ; Lucentini, Lucio ; Di Mario, Umberto. / T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. In: European Journal of Endocrinology. 1999 ; Vol. 141, No. 3. pp. 272-278.
@article{5e3fd4f511db40ba861b3977f0d8f72e,
title = "T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus",
abstract = "The target molecules of the T-cell response in type 1 diabetes, despite their pathogenic importance, remain largely uncharacterized, especially in humans. Interestingly, molecules such as insulin and glutamic acid decarboxylase (GAD) have been shown to be a target not only of autoantibodies, but also of autoreactive T-lymphocytes both in man and in the non-obese diabetic (NOD) mouse. In the present study we aimed to determine the existence of a specific T-cell response towards the insulinoma-associated protein 2 (IA-2) islet tyrosine phosphatase, a recently identified autoantigen which is the target of autoantibodies strongly associated with diabetes development. Human recombinant IA-2 produced in Escherichia coli, was tested for its reactivity with peripheral blood lymphocytes obtained from 16 newly diagnosed type i diabetic patients and from 25 normal controls, 15 of whom were HLA-DR-matched. A T-cell proliferation assay was performed in triplicate employing freshly isolated cells in the absence or in the presence of the antigen to be tested (at two different concentrations: 2 μg/ml and 10 μg/ml). A specific T-cell proliferation (defined as a stimulation index (S.I.) ≥3) was observed against IA-2 used at a concentration of 10 μg/ml (but not of 2 μg/ml) in 8/16 diabetic patients, in 1/15 HLA-DR-matched control subjects (P <0.01 by Fisher exact test) and in 0/10 of the remaining normal individuals. A statistically significant difference (P <0.003 by Mann-Whitney U test) was also observed in S.I. values between patients (3.1 ± 1.4) and HLA-DR-matched controls (1.7 ± 0.54) employing IA-2 at a concentration of 10 μg/ml. However, when IA-2 was used at a concentration of 2 μg/ml, the difference in S.I. between patients (1.65 ± 0.8) and controls (1.0 ± 0.3) did not reach statistical significance. In conclusion, these data show the presence of a specific, dose-dependent T-lymphocyte response against the IA-2 islet tyrosine phosphatase at the onset of type 1 diabetes. Consequently, this molecule appears to be a target not only at the B- lymphocyte but also at the T-lymphocyte level, reinforcing the potential pathogenic role of this autoantigen in the islet destructive process.",
author = "Francesco Dotta and Sabrina Dionisi and Vissia Viglietta and Claudio Tiberti and Matteoli, {Maria Cristina} and Marco Cervoni and Carla Bizzarri and Giovanni Marietti and Manuela Testi and Giuseppe Multari and Lucio Lucentini and {Di Mario}, Umberto",
year = "1999",
month = "9",
doi = "10.1530/eje.0.1410272",
language = "English",
volume = "141",
pages = "272--278",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus

AU - Dotta, Francesco

AU - Dionisi, Sabrina

AU - Viglietta, Vissia

AU - Tiberti, Claudio

AU - Matteoli, Maria Cristina

AU - Cervoni, Marco

AU - Bizzarri, Carla

AU - Marietti, Giovanni

AU - Testi, Manuela

AU - Multari, Giuseppe

AU - Lucentini, Lucio

AU - Di Mario, Umberto

PY - 1999/9

Y1 - 1999/9

N2 - The target molecules of the T-cell response in type 1 diabetes, despite their pathogenic importance, remain largely uncharacterized, especially in humans. Interestingly, molecules such as insulin and glutamic acid decarboxylase (GAD) have been shown to be a target not only of autoantibodies, but also of autoreactive T-lymphocytes both in man and in the non-obese diabetic (NOD) mouse. In the present study we aimed to determine the existence of a specific T-cell response towards the insulinoma-associated protein 2 (IA-2) islet tyrosine phosphatase, a recently identified autoantigen which is the target of autoantibodies strongly associated with diabetes development. Human recombinant IA-2 produced in Escherichia coli, was tested for its reactivity with peripheral blood lymphocytes obtained from 16 newly diagnosed type i diabetic patients and from 25 normal controls, 15 of whom were HLA-DR-matched. A T-cell proliferation assay was performed in triplicate employing freshly isolated cells in the absence or in the presence of the antigen to be tested (at two different concentrations: 2 μg/ml and 10 μg/ml). A specific T-cell proliferation (defined as a stimulation index (S.I.) ≥3) was observed against IA-2 used at a concentration of 10 μg/ml (but not of 2 μg/ml) in 8/16 diabetic patients, in 1/15 HLA-DR-matched control subjects (P <0.01 by Fisher exact test) and in 0/10 of the remaining normal individuals. A statistically significant difference (P <0.003 by Mann-Whitney U test) was also observed in S.I. values between patients (3.1 ± 1.4) and HLA-DR-matched controls (1.7 ± 0.54) employing IA-2 at a concentration of 10 μg/ml. However, when IA-2 was used at a concentration of 2 μg/ml, the difference in S.I. between patients (1.65 ± 0.8) and controls (1.0 ± 0.3) did not reach statistical significance. In conclusion, these data show the presence of a specific, dose-dependent T-lymphocyte response against the IA-2 islet tyrosine phosphatase at the onset of type 1 diabetes. Consequently, this molecule appears to be a target not only at the B- lymphocyte but also at the T-lymphocyte level, reinforcing the potential pathogenic role of this autoantigen in the islet destructive process.

AB - The target molecules of the T-cell response in type 1 diabetes, despite their pathogenic importance, remain largely uncharacterized, especially in humans. Interestingly, molecules such as insulin and glutamic acid decarboxylase (GAD) have been shown to be a target not only of autoantibodies, but also of autoreactive T-lymphocytes both in man and in the non-obese diabetic (NOD) mouse. In the present study we aimed to determine the existence of a specific T-cell response towards the insulinoma-associated protein 2 (IA-2) islet tyrosine phosphatase, a recently identified autoantigen which is the target of autoantibodies strongly associated with diabetes development. Human recombinant IA-2 produced in Escherichia coli, was tested for its reactivity with peripheral blood lymphocytes obtained from 16 newly diagnosed type i diabetic patients and from 25 normal controls, 15 of whom were HLA-DR-matched. A T-cell proliferation assay was performed in triplicate employing freshly isolated cells in the absence or in the presence of the antigen to be tested (at two different concentrations: 2 μg/ml and 10 μg/ml). A specific T-cell proliferation (defined as a stimulation index (S.I.) ≥3) was observed against IA-2 used at a concentration of 10 μg/ml (but not of 2 μg/ml) in 8/16 diabetic patients, in 1/15 HLA-DR-matched control subjects (P <0.01 by Fisher exact test) and in 0/10 of the remaining normal individuals. A statistically significant difference (P <0.003 by Mann-Whitney U test) was also observed in S.I. values between patients (3.1 ± 1.4) and HLA-DR-matched controls (1.7 ± 0.54) employing IA-2 at a concentration of 10 μg/ml. However, when IA-2 was used at a concentration of 2 μg/ml, the difference in S.I. between patients (1.65 ± 0.8) and controls (1.0 ± 0.3) did not reach statistical significance. In conclusion, these data show the presence of a specific, dose-dependent T-lymphocyte response against the IA-2 islet tyrosine phosphatase at the onset of type 1 diabetes. Consequently, this molecule appears to be a target not only at the B- lymphocyte but also at the T-lymphocyte level, reinforcing the potential pathogenic role of this autoantigen in the islet destructive process.

UR - http://www.scopus.com/inward/record.url?scp=0032877727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032877727&partnerID=8YFLogxK

U2 - 10.1530/eje.0.1410272

DO - 10.1530/eje.0.1410272

M3 - Article

C2 - 10474125

AN - SCOPUS:0032877727

VL - 141

SP - 272

EP - 278

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 3

ER -